Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfiercebiotech.com
FierceBiotech
Get the latest updates from FierceBiotech directly as they happen.
Follow now 344 followers
Latest posts
Last updated about 17 hours ago
Novartis ends ALS program after phase 2 flop, adding to R&D woes
about 17 hours ago
Novartis has extended its losing streak, stopping an amyotrophic lateral sclerosis program...
Novartis pays Sironax $125M to acquire platform for crossing the blood-brain barrier
about 19 hours ago
Novartis is paying Sironax $125 million to take up its option on...
CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’
about 20 hours ago
Following a steady stream of acquisitions that culminated in three biotech buyouts...
Sling reels in $123M series C to fund oral Tepezza rival through phase 3 trial
about 21 hours ago
Sling Therapeutics has closed a $123 million series C round to advance...
Mayo Clinic teams with Thermo Fisher to form biomedical data group Precure
1 day ago
The Mayo Clinic has partnered with Thermo Fisher Scientific to launch a...
FDA launches pilot program to speed up sluggish phase 1 trials
1 day ago
After teasing a new initiative to speed up early-stage clinical trials over...
Newly formed Jaguar acquires Afib device assets from J&J
1 day ago
Jaguar LAA, a newly formed medtech, has acquired assets that are part...
Connect's Dupixent rival flunks phase 2 asthma trial, but biotech sees reasons for hope
1 day ago
Connect Biopharma’s hopes of dethroning Dupixent took a knock as its IL-4/IL-13...
Lilly pledges up to $237M per program in CNS genetic med collab with Canadian biotech
1 day ago
Eli Lilly’s ongoing attempt to strengthen its genetic medicine offering has seen...
Sionna lays off 46% of workforce in strategic shift after cystic fibrosis trial fail
1 day ago
Sionna Therapeutics is laying off almost half its workforce as the company...
After rejection, FDA approves Telix’s Pixclara, the first FET-PET imaging drug for brain cancer
2 days ago
The FDA has signed off on the first ever glioma drug imaging...
GSK doubles down on Chimagen with $750M multiple myeloma wager
2 days ago
GSK has bet up to $750 million on a Chimagen Biosciences trispecific...